Research programme: HER2 receptor modulators - IBI-Lorenzini Istituto-Biochimico-Italiano-G-LorenziniAlternative Names: anti-HER2 humanized monoclonal antibody
Latest Information Update: 16 Sep 2016
At a glance
- Originator Istituto Biochimico Italiano G Lorenzini
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer